کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5912150 1570210 2016 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics
ترجمه فارسی عنوان
بررسی اصول اخلاقی استفاده از دارونما در آزمایشات بالینی برای درمان بیماریهای مولتیپل اسکلروزیس مجدد
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی ژنتیک
چکیده انگلیسی
Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-controlled trials. Since then, the ethics of the continued use of placebo in clinical trials of new DMTs for RRMS has been the subject of repeated policy statements and recommendations by international committees. As further data have accumulated demonstrating a reduction in long-term morbidity and mortality with early initiation of DMT, a growing consensus has emerged that further inclusion of placebo arms in clinical trials of novel RRMS therapies is no longer ethical.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Multiple Sclerosis and Related Disorders - Volume 7, May 2016, Pages 109-112
نویسندگان
, ,